ICORG to broaden membership and executive

28th July 2003: The Irish Clinical Oncology Research Group (ICORG), which continues to attract international research programmes to Ireland enabling Irish hospitals to participate in leading-edge clinical research, whilst ensuring that Irish patients get access to the very latest oncology treatments, has just issued a major constitutional change. This change will broaden the membership, which is currently only open to clinical specialists in the fields of medical, radiation and surgical oncology, and remit of ICORG considerably.

The constitutional change, approved by 95% of current members who voted in the referendum, means that ICORG will see the formation of a new Principal Investigators Committee. This will be composed of all principal investigators from participating hospitals or regions. ICORG membership will be expanded to include Research Specialists, including translational scientists, clinical scientists, research professionals, cancer research nurses and co-ordinators.

The change will also see the appointment of a member of Irish Cancer Society, which is the biggest source of ICORG’s financial support, to the ICORG Executive and the appointment of a Lead Principal Investigator, Haematologic Modality Leader and Research Specialist Modality Leader to the ICORG Executive, meaning the ICORG executive will expand from 6 to 11.

ICORG is a professional, not for profit organisation, established in 1996. To date ICORG has set up 38 research studies in Ireland, with close to 1,000 patients participating in these trials.

For further information, please contact Dr. Brian Moulton, CEO, ICORG at 01 6677211 or email to: .(JavaScript must be enabled to view this email address) or mail to: ICORG, 120 Pembroke Road,
Dublin 4.